Hanaka Junichi, Hashimoto Shinji, Takahashi Shinji, Okuda Yoichi, Kanamura Shigeru, Hara Akihiro, Kyoku Keicho, Akiyama Koki, Takahashi Misaki, Goya Tomoyuki
Dept. of Pharmacy, Koyama Memorial Hospital.
Gan To Kagaku Ryoho. 2021 Sep;48(9):1165-1167.
A 74-year-old man presented to our hospital because of anorexia. Upper gastrointestinal endoscopy revealed type 3 gastric cancer. Further examination disclosed metastasis to the perigastric lymph nodes and to the liver, and a diagnosis of non- resectable advanced gastric cancer(cT4N2H1P0M0)in cStage Ⅳ was made. A total of 4 courses of S-1 plus oxaliplatin therapy(80 mg/body/day and 100 mg/m2/cycle, respectively, for 2 weeks followed by a 1-week rest)were administered as the primary chemotherapy. Then, another metastasis to the abdominal lymph nodes and increased liver metastasis were found; thus, the patient's condition was rated as progressive disease(PD). Secondary chemotherapy comprising 10 courses of weekly nab-paclitaxel(nab-PTX)plus ramucirumab(RAM)therapy(100 mg/m2 on days 1, 8, and 15 and 8 mg/kg on days 1 and 15, respectively, every 4 weeks)were administered. Although temporary reductions in the perigastric lymph node metastasis and liver metastasis as compared with the baseline were observed, another metastasis to the abdominal lymph nodes occurred subsequently, resulting in PD. As tertiary chemotherapy, nivolumab therapy(240 mg/body, every 3 weeks) was repeated up to a total of 30 courses over 13 months. This therapy was markedly effective, achieving a near complete response. The patient is currently being followed up as an outpatient.
一名74岁男性因厌食症前来我院就诊。上消化道内镜检查显示为3型胃癌。进一步检查发现胃周淋巴结和肝脏转移,诊断为不可切除的晚期胃癌(cT4N2H1P0M0),临床分期为Ⅳ期。作为一线化疗,共给予4个疗程的S-1联合奥沙利铂治疗(分别为80mg/体/天和100mg/m²/周期,持续2周,随后休息1周)。然后,发现腹部淋巴结出现新的转移且肝转移增加;因此,患者病情被评定为疾病进展(PD)。二线化疗采用每周一次的纳武单抗(nab-PTX)联合雷莫西尤单抗(RAM)治疗,共10个疗程(分别在第1、8和15天给予100mg/m²,在第1和15天给予8mg/kg,每4周一次)。虽然观察到与基线相比胃周淋巴结转移和肝转移暂时减少,但随后腹部淋巴结又出现转移,导致疾病进展。作为三线化疗,纳武单抗治疗(240mg/体,每3周一次)共重复进行了30个疗程,持续13个月。该治疗效果显著,达到了近乎完全缓解。患者目前作为门诊病人接受随访。